Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
62.76
+20.82 (49.64%)
At close: Mar 9, 2026, 4:00 PM EDT
62.01
-0.75 (-1.20%)
After-hours: Mar 9, 2026, 5:39 PM EDT
Xenon Pharmaceuticals Revenue
In the year 2025, Xenon Pharmaceuticals had annual revenue of $7.50M.
Revenue (ttm)
$7.50M
Revenue Growth
n/a
P/S Ratio
675.95
Revenue / Employee
$20,270
Employees
370
Market Cap
5.22B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.73B |
| Caris Life Sciences | 812.03M |
| Mirum Pharmaceuticals | 521.31M |
| CG Oncology | 4.04M |
| CRISPR Therapeutics AG | 3.51M |
XENE News
- 1 hour ago - Xenon Pharmaceuticals Announces Proposed Public Offering - GlobeNewsWire
- 3 hours ago - Crude Oil Rises Around 4%; Xenon Pharmaceuticals Shares Surge - Benzinga
- 3 hours ago - Xenon Pharmaceuticals Inc. (XENE) Discusses Positive Top Line Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures Transcript - Seeking Alpha
- 6 hours ago - Xenon: Shares Soar On Seizure Data, But Valuation May Be Overcooked - Seeking Alpha
- 8 hours ago - Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures - Benzinga
- 10 hours ago - Xenon Pharma's epilepsy drug meets main goal in late-stage trial - Reuters
- 10 hours ago - Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) - GlobeNewsWire
- 1 day ago - Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026 - GlobeNewsWire